Scleroderma, a rare and often perplexing autoimmune disorder, presents numerous challenges for both patients and drug development organizations. One key tool in unravelling the mysteries of this condition is medical imaging. From diagnosing scleroderma to monitoring disease progression and assessing treatment effectiveness, various imaging modalities play a crucial role in the care of individuals affected by this disease.
IAG team helps pharmaceutical companies to use medical imaging and associated digital endpoints to support diagnosis / screening, assessment of organ involvement, disease progression monitoring and drug efficacy assessment using MRI, US, Xray, CT and other available imaging modalities.
IAG and University of Leeds, UK have partnered to develop a novel Digital Arteries Volume Index, DAVIX, which was used in drug development trials since 2010. DAVIX© has been validated as a predictor of the onset of Digital Ulcers in Systemic Sclerosis patients. This innovative methodology is based on the Time-of-Flight Magnetic Resonance Imaging (MRI) angiography and allows to quantitatively assess digital arterial blood flow.
- Screening: Scleroderma’s hallmark symptom is skin thickening, but it can also affect internal organs, making early and accurate diagnosis critical. Imaging, such as high-resolution ultrasound and magnetic resonance imaging (MRI), is instrumental in detecting abnormalities within affected tissues and organs. These techniques help clinicians visualize the extent and location of fibrosis, a key feature of scleroderma, and can aid in differentiating the disease from other conditions with similar symptoms.
- Assessing Organ Involvement: Scleroderma doesn’t stop at the skin; it often targets vital organs such as the lungs, heart, and gastrointestinal tract. Imaging studies like chest X-rays, CT scans, and echocardiograms can provide vital information about the extent of organ involvement, helping doctors tailor treatment plans to individual patients.
- Disease Progression Monitoring: Scleroderma is a progressive disease, and regular monitoring is essential to track changes in organ function and tissue involvement. Imaging allows for ongoing assessment without invasive procedures, providing valuable data for treatment adjustments and long-term management.
- Evaluating Treatment Efficacy: Many treatment options are available to manage scleroderma, but their effectiveness varies from person to person. Imaging can help healthcare providers gauge how well treatment is working by tracking changes in organ function, tissue thickness, and inflammation levels.
Imaging plays a pivotal role in scleroderma research. By visualizing the disease at the cellular and molecular levels, scientists can gain deeper insights into its underlying mechanisms and develop more targeted therapies.
IAG’s team plays an active role in the scientific community and have led the development of novel scoring systems for early assessment of synovial inflammatory changes, quantification of inflammation (bone marrow oedema and synovial) and quantitative assessment of erosive changes.
About IAG, Image Analysis Group
IAG, Image Analysis Group is a strategic partner to bio-pharmaceutical companies developing new treatments to improve patients’ lives. Our dynamic Strategy, Trial Solutions and Bio-Partnering divisions work closely to meet critical needs of biotechnology companies: funding, clinical development, and monetization of their assets. We fuse decades of therapeutic insights, risk-sharing business model and agile culture to accelerate novel drug development. IAG broadly leverages its core imaging expertise, proprietary technology platform DYNAMIKA and capabilities to support an objective early go no/ go decision and drive excellence for tomorrow’s innovative therapeutic agents with speed.
Contact our expert team: imaging.experts @ ia-grp.com
Experience: Scoring Systems
- Eligibility and Safety Assessments
- DAVIX (Digital Arteries Volume Index)
- Quantitative Inflammation (DEMRIQ)
- Organ Involvement (Xray or CT)
- US-Doppler Quantification
Since 2007, over 2000 articles were published to cover scientific discoveries, technology break-throughs and special cases. We list here some critically important papers and abstracts.
Combining our technologies and business advisory services with promising life science companies has yielded spectacular results over the past five years. As a trusted partner to many biotech and pharma companies, IAG’s team is proud to share your words and quotes.